Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd boosted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 22.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,428 shares of the medical equipment provider's stock after purchasing an additional 5,671 shares during the quarter. UniSuper Management Pty Ltd's holdings in Hologic were worth $2,194,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in HOLX. General Partner Inc. bought a new position in Hologic during the fourth quarter valued at approximately $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC grew its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HOLX. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price for the company. Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Stock Up 0.8 %

HOLX traded up $0.47 during trading on Thursday, hitting $61.03. The stock had a trading volume of 1,424,935 shares, compared to its average volume of 2,404,510. The stock has a 50 day simple moving average of $64.69 and a two-hundred day simple moving average of $72.88. The company has a market capitalization of $13.69 billion, a PE ratio of 19.25, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a twelve month low of $59.06 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.